The oncoproteins MDM2 and MDMX negatively regulate the activity and stability of the tumor suppressor protein p53, conferring tumor development and survival. Antagonists targeting the p53-binding domains of MDM2 and MDMX kill tumor cells both in vitro and in vivo by reactivating the p53 pathway, promising a class of antitumor agents for cancer therapy. Aided by native chemical ligation and mirror image phage display, we recently identified a D-peptide inhibitor of the p53-MDM2 interaction termed 
mirror-image phage display | native chemical ligation | glioblastoma T he tumor suppressor protein p53 is a transcription factor that transactivates, in response to cellular stresses, the expression of various target genes that mediate cell cycle arrest, senescence, or apoptosis (1) . Dubbed the "guardian of the genome" (2), p53 is critical for maintaining genetic stability and preventing tumor development (3) . Not surprisingly, loss of p53 activity resulting from point mutations in the TP53 gene is responsible for approximately 50% of human tumors. Although p53 retains WT status in many other tumors, its tumor suppressor activity and in vivo stability are abrogated by regulatory molecules such as the E3 ubiquitin ligase MDM2 and its homologue MDMX (4, 5) . Amplified or over-expressed in a significant fraction of cancers without concomitant TP53 mutation, MDM2 and MDMX directly contribute to p53 inactivation and tumor survival.
MDM2 itself is transcriptionally inducible by p53 in a negative feedback loop (6) . MDM2 binds the N-terminal transactivation domain of p53 with high affinity to block p53 regulating responsive gene expression (7) . More importantly, MDM2 controls p53 stability by targeting the tumor suppressor protein for ubiquitinmediated constitutive degradation (8) (9) (10) . Although MDMX lacks E3 ubiquitin ligase activity, the MDM2 homologue acts as an effective transcriptional antagonist of p53, and nonredundantly impedes p53-induced growth inhibitory and apoptotic responses (4, 5) . In addition, MDMX forms heterodimers with MDM2 through their C-terminal RING finger domains, stimulating MDM2-mediated ubiquitination and degradation of p53 and MDMX itself (11-13). The interplay between MDM2 and MDMX confers a robust p53 inactivation in tumorigenesis (14) .
Recent studies show that restoring endogenous p53 activity can halt the growth of cancerous tumors in mice through cell typedependent multiple mechanisms, including apoptosis, senescence, and senescence-triggered innate inflammatory responses (15) (16) (17) . Thus, antagonists of MDM2 and MDMX that activate the p53 pathway can potentially be developed into a class of therapeutic agents for cancer treatment (14) . Much of the current efforts have been focused on combinatorial library search for and structurebased rational design of low molecular weight antagonists of MDM2 (18) . Successful examples include a cis-imidazoline analogue, termed nutlin-3, and, a spiro-oxindole-derived compound, termed MI-219 (19, 20) . For optimal efficacy, however, dual specific inhibitors may be needed to target both MDM2 and MDMX (14) .
We previously reported the synthesis of the p53-binding domain of MDM2 ( MDM2) and its site-specifically biotinylated form using native chemical ligation (21) (22) (23) . Screening a duodecimal peptide phage library against biotinylated MDM2 led to the identification of a potent dual specificity peptide inhibitor termed PMI (p53-MDM2/MDMX inhibitor, TSFAEYWNLLSP). PMI bound to MDM2 and MDMX in their p53-binding cavities with low nanomolar affinities (23) . As L-peptide inhibitors are inherently "undruggable" as potential therapeutic agents as a result of their poor in vivo stability, we have applied mirror-image phage display (24, 25) to the discovery of a proteolysis-resistant D-peptide inhibitor of the p53-MDM2 interaction, termed MDM2 at affinities of 219 and 35 nM, respectively, but failed to induce p53-dependent tumor cell death as a result of their inability to traverse the cell membrane. Here we report the identification and characterization of a distinct high-affinity D-peptide inhibitor that binds to the p53-binding pocket of MDM2, and demonstrate the therapeutic efficacy of liposome-encapsulated D-peptide activators of p53 in the treatment of malignant neoplasms harboring WT p53 and elevated levels of MDM2.
Results
Mirror-Image Phage Display. For mirror-image phage display, we prepared N79K-biotin-D- MDM2 composed entirely of Damino acids as described (23, 26) . The D-protein was correctly folded and fully functional (SI Appendix, Figs. S1 and S2). We screened the Ph.D.-12 duodecimal peptide phage library against 100 nM N79K-biotin-D- MDM2 immobilized on streptavidin-agarose resin (as opposed to 1 μM used in the selection of D PMI-α). Phage particles bound to the D-protein were competitively eluted with 1 mM D- [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] p53, and subsequently amplified in host strain Escherichia coli ER2738. After four rounds of selection, 10 plaques were picked at random and their amplified DNAs were sequenced, of which seven binding clones gave rise to the following sequence: DWWPLAFEALLR. A second independent screening experiment confirmed this result (SI Appendix, Fig. S3 ).
Functional Validation of D PMI-γ as a p53 Activator. We quantified the binding affinity of the D-enantiomer of the phage-selected peptide, termed MDM2 and MDMX using competition surface plasmon resonance (23, 27, 28) Fig. S9) MDM2 itself is transcriptionally inducible by p53 in a negative feedback loop essential for maintaining low levels of p53 during normal development (35, 36) , whereas the p53 responsive gene p21 encodes a cyclin-dependent kinase inhibitor that regulates cell cycle progression (37) (38) (39) . To further investigate the mechanisms of action of intracellular D PMI-α, we analyzed the expression of MDM2 and p21 in U87 and U251 cells by Western blotting. As shown in Fig. 3B , 12 h after treatment with RGDliposome-D PMI-α, dose-dependent induction of p53, MDM2, and p21 became evident in U87 cells. By contrast, basal levels of (mutant) p53 were maintained and no expression of MDM2 and p21 was detected in U251 cells. These findings strongly support that intracellular D PMI-α inhibited U87 cell growth by reactivating the p53 pathway. PMI-α at low dose was effective in slowing tumor growth compared with mock treatment (P < 0.05). Remarkably, the high-dosage group showed tumor growth inhibition and no signs of weight loss were observed (P < 0.01).
In the second animal model, four groups of intracranial glioblastoma-bearing mice (n = 6) were treated via tail vein with multiple doses of saline solution, RGD-liposome-doxorubicin at 5 mg/kg, or RGD-liposome- (Fig. 4B Inset) .
Discussion
In mirror-image phage display (24, 25) phage-expressed peptide libraries are screened against the D-enantiomer of a native protein of interest, yielding an L-peptide ligand that binds specifically to the D-protein. After enantiomeric inversion, the resultant D-peptide ligand, for reasons of symmetry, binds specifically to the native L-protein with the same affinity. Mirrorimage phage display takes advantage of vast biodiversity presented by a phage library and affords an elegant and powerful tool for the discovery of potent and proteolysis-resistant Dpeptides for therapeutic applications (24, 25, 40, 41) . As total chemical synthesis is the only method to generate D-proteins for phage library screening, mirror image phage display is limited to the protein targets that are chemically accessible, and, thus, has rarely been practiced in drug discovery. Kent and colleagues pioneered native chemical ligation, a revolutionary synthetic methodology that enables two or more fully unprotected synthetic peptides to react chemoselectively in aqueous solution, yielding a longer polypeptide chain linked in native peptide bonds (21, 22) . As its debut, native chemical ligation has been (29, (46) (47) (48) . Conjugation of the hydrophobic peptide D PMI-γ to a cluster of Arg residues likely generated a detergent-like molecule that would be indiscriminately toxic against all cell types.
The apparent failure of D PMI-γ-D R9 to preferentially kill HCT116 p53 +/+ cells in a p53-dependent manner demonstrates the limited value of cationic cell-penetrating peptides in delivering hydrophobic cargo, and underscores the need to develop alternative clinically viable cellular delivery vehicles for therapeutic peptides and proteins. Particularly noteworthy in this regard is the hydrocarbon stapling technique developed by Verdine and colleagues, which enables side-chain cross-linked α-helical peptides to actively traverse the cell membrane with enhanced biological activity and proteolytic stability (49) . Several hydrocarbon-stapled peptides that antagonize intracellular proteins have been designed to inhibit tumor growth in cell cultures and/or experimental animals (50) (51) (52) . It is conceivable that a hydrocarbon-stapled D-peptide antagonist of MDM2, when properly designed, may exert robust p53-dependent antitumor activity in vivo as a result of its full resistance to proteolytic degradation. Our work reported here validates liposomes as therapeutically viable D-peptide carriers for targeted molecular therapy.
Glioblastoma multiforme (GBM) is the most common and most malignant type of brain cancer and has an extremely poor prognosis (53) . GBM remains very difficult to treat in part because of severe side effects associated with and resistance to conventional genotoxic chemotherapies compounded by the blood-brain barrier to many drugs. New therapies are needed that exploit aberrant activation or suppression of cellular signal transduction pathways impaired by underlying genetic abnormalities in GBM. A majority of GBM harbors WT p53 concurrent with amplification or overexpression of MDM2 and MDMX or deletion of the MDM2 inhibitor ARF (54) . Antisense anti-MDM2 oligonucleotides have been shown to inhibit glioblastoma growth in vitro and in vivo in a p53-dependent manner (55) . We have demonstrated that D-peptide antagonists of MDM2, when encapsulated in liposomes decorated with an integrin-targeting cyclic-RGD peptide, exert potent growth inhibitory activity against human glioblastoma in experimental animals. In vitro mechanistic studies suggest that D PMI-α inhibits tumor growth by reactivating the p53 pathway. Our work validates D-peptide antagonists of MDM2 as a unique class of p53 activators with potential therapeutic value in the treatment of not only GBM, but many other malignant neoplasms harboring WT p53 and elevated levels of MDM2 as well.
Of note, much of the current efforts have been focused on the development of small-molecule antagonists of MDM2 and/or MDMX for p53-dependent anticancer therapy, and several of them are in early clinical trials (14, 19, 20) . D-peptides as therapeutic agents are attractive in view of their ability to bind and antagonize target proteins with high affinity and unsurpassed specificity; their resistance to proteolytic degradation in vivo should translate into excellent bioavailability. To achieve optimal therapeutic efficacy of 
Materials and Methods
Crystallization, Data Collection, Structure Determination, and Refinement. Crystallization screening of the D PMI-γ- MDM2 complex was conducted at room temperature using the hanging-drop vapor diffusion method and commercial crystallization matrices (Hampton). The best crystals were grown upon mixing 1 μL of D PMI-γ- MDM2 at approximately 10 mg/mL in 10 mM Hepes buffer, 0.1 mM TCEP, pH 7.5, with 1 μL of 0.05 M potassium phosphate monobasic solution containing 20% PEG 8,000. X-ray diffraction data were collected with a Raxis-4++ image plate detector mounted on a Rigaku-MSC Micromax 7 generator (at the x-ray crystallography core facility at University of Maryland, Baltimore, MD). Data integration and scaling, and structure solution and refinement were performed as described (23) . The previously determined structure of MDM2 in complex with PMI (3EQS) was used as a search model for molecular replacement. Data collection and refinement statistics are summarized in Table S1 in the SI Appendix. The coordinates and structure factors have been deposited in the PDB with accession code 3IWY. Molecular graphics were generated using Pymol (http://pymol.org).
MTT Cell Viability Assay. Human glioblastoma cancer cell lines U87 and U251 were cultured in DMEM supplemented with 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin at 37°C with 5% CO 2 under fully humidified conditions. Cells were seeded at 3,000 cells/well in 96-well plates and allowed to grow for 24 h before treatment. Spectroscopic readings were Western Blot Analysis. The protein fraction of cell lysates was resolved by 10% SDS/PAGE before membrane transfer. Primary antibodies were from Bioworld Technology (p53 and MDM2), Santa Cruz Biotechnology (p21), and Sigma-Aldrich (β-actin); secondary antibodies conjugated with horseradish peroxidase were from Bio-Rad Laboratories.
Growth Inhibition of Glioblastoma in Xenograft Models. Male BALB/c nude mice, 6 to 8 wk old, were inoculated with 6× 10 6 U87 cells (in 200 μL of media) in the s.c. tissue of the right shoulder blade. Tumor volumes were calculated on the basis of caliper measurements using the following formula:
Tumor volume ¼ h length × ðwidthÞ 2 i. 2
Treatment of four groups of mice (six mice per group) was initiated (i.e., time 0) after the tumor had been established in 2 wk as a palpable mass (50-120 mm 3 in size). RGD-liposome-doxorubicin was administered at a dose of 2.5 mg/kg on d 1, 6, and 11. RGD-liposome-D PMI-α was administered at high (7.5 mg/kg) and low (3 mg/kg) doses on d 1, 3, 5, 8, 10, and 12. Saline solution was used as a negative control. For intracranial tumor establishment, male BALB/c nude mice, 6 to 8 wk old, were anesthetized and slowly injected with U87 cells (5× 10 5 cells suspended in 5 μL PBS solution) into the right striatum (1.8 mm lateral and 0.6 mm anterior to bregma at 3 mm depth). Four groups of intracranial U87-bearing mice (six mice per group) were treated with saline solution; RGD-liposome-D PMI-α at high (10 mg/kg) and low (4 mg/kg) doses on d 6, 8, 10, 12, 14, 16, 18 , and 20 after inoculation; and RGD-liposome-doxorubicin at 5 mg/kg on d 6, 10, 14, and 18 after inoculation.
